Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer
BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--Ifinatamab deruxtecan (I-DXd) has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the tre...
What are the risks and upside scenarios surrounding upcoming clinical trial data or regulatory milestones for I‑DXd that could drive significant price volatility?
What is the potential market size and competitive landscape for B7‑H3 directed ADCs in extensive‑stage small cell lung cancer, and how might this influence Daiichi Sankyo's revenue forecasts?
How will the Breakthrough Therapy Designation affect Ifinatamab deruxtecan's expected FDA approval timeline and market valuation of Daiichi Sankyo (DSKY)?
6 days ago